ES2188665T3 - Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion. - Google Patents

Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.

Info

Publication number
ES2188665T3
ES2188665T3 ES95921780T ES95921780T ES2188665T3 ES 2188665 T3 ES2188665 T3 ES 2188665T3 ES 95921780 T ES95921780 T ES 95921780T ES 95921780 T ES95921780 T ES 95921780T ES 2188665 T3 ES2188665 T3 ES 2188665T3
Authority
ES
Spain
Prior art keywords
fragments
preparation
cardiodylatin
purified
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921780T
Other languages
English (en)
Inventor
Hansueli Immer
Wolf-Georg Forssmann
Knut Adermann
Christian Klessen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FORSSMANN WOLF-GEORG PROF DR MED
Original Assignee
FORSSMANN WOLF-GEORG PROF DR MED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19513784A external-priority patent/DE19513784A1/de
Application filed by FORSSMANN WOLF-GEORG PROF DR MED filed Critical FORSSMANN WOLF-GEORG PROF DR MED
Application granted granted Critical
Publication of ES2188665T3 publication Critical patent/ES2188665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION TRATA DE UN PROCEDIMIENTO PARA LA OBTENCION DE FRAGMENTOS DE CARDIODILATINA, FRAGMENTOS DE CARDIODILATINA MUY PURIFICADOS Y LOS CORRESPONDIENTES PRODUCTOS INTERMEDIOS PARA LA OBTENCION DE ESTOS FRAGMENTOS. ADEMAS TRATA LA INVENCION DE FRAGMENTOS DE CARDIODILATINA MUY PURIFICADOS, QUE ESTAN LIBRES DE IMPUREZAS PEPTIDICAS Y QUE TIENEN UN UNICO MAXIMO DE MIGRACION EN LA ELECTROFORESIS CAPILAR, ASI COMO LOS CORRESPONDIENTES PROCEDIMIENTOS PARA SU OBTENCION
ES95921780T 1994-06-02 1995-05-30 Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion. Expired - Lifetime ES2188665T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4420381 1994-06-02
DE19513784A DE19513784A1 (de) 1994-06-02 1995-04-10 Hochreines Urodilatin und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
ES2188665T3 true ES2188665T3 (es) 2003-07-01

Family

ID=25937342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921780T Expired - Lifetime ES2188665T3 (es) 1994-06-02 1995-05-30 Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.

Country Status (8)

Country Link
US (5) US5767239A (es)
EP (1) EP0763061B1 (es)
JP (2) JPH10500969A (es)
AT (1) ATE226960T1 (es)
AU (1) AU2671795A (es)
ES (1) ES2188665T3 (es)
IL (1) IL113979A0 (es)
WO (1) WO1995033769A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500969A (ja) * 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
CA2345414A1 (en) * 1998-09-28 2000-04-06 Santen Pharmaceutical Co., Ltd. Eyedrops for promoting lacrimal secretion or treating keratoconjunctival disorders containing natriuretic peptide as active ingredient
UA71608C2 (en) * 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
WO2006041945A2 (en) * 2004-10-04 2006-04-20 Novetide, Ltd. A counterion exchange process for peptides
EP2510942B1 (en) 2005-04-07 2015-09-02 Cardiorentis AG Use of natriuretic peptide for treating heart failure
AU2008279379B2 (en) * 2007-07-20 2016-03-24 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2009086166A1 (en) * 2007-12-19 2009-07-09 Ekr Therapeutics, Inc. Room temperature stable, lyophilized natriuretic peptide formulations
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
JP6108858B2 (ja) 2012-02-17 2017-04-05 株式会社半導体エネルギー研究所 ｐ型半導体材料および半導体装置
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EA201500765A1 (ru) 2013-01-25 2015-12-30 Кардиорентис Лтд. Способы лечения сердечно-сосудистых заболеваний
CN103145827A (zh) * 2013-03-04 2013-06-12 吉尔生化（上海）有限公司 一种乌拉力肽的固相合成方法
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2016131943A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes
EP3337894A1 (en) 2015-08-17 2018-06-27 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
CN106928342B (zh) * 2015-12-31 2020-10-16 深圳翰宇药业股份有限公司 一种乌拉立肽的制备方法
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
JP2020512363A (ja) 2017-03-31 2020-04-23 アレクシオン ファーマシューティカルズ， インコーポレイテッド 成人及び青年における低ホスファターゼ症（ｈｐｐ）を治療する方法
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
EP3805246B1 (en) * 2018-05-30 2025-02-19 Hybio Pharmaceutical Co., Ltd. Method for purifying long chain polypeptide ularitide
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN110845599B (zh) * 2018-08-21 2022-10-14 鲁南制药集团股份有限公司 一种多肽的制备纯化方法
JP7796645B2 (ja) 2019-12-09 2026-01-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
WO2022029499A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Methods of treating refractory ascites
WO2022029497A1 (en) 2020-08-06 2022-02-10 Ads Aiphia Development Services Ag Ularitide for use in methods of treating refractory ascites
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof
CA3217598A1 (en) 2021-05-06 2022-11-10 Par Ingemar Johansson Diagnosing and treating critically ill subjects

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
DE3346953A1 (de) * 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
ATE120759T1 (de) * 1984-04-19 1995-04-15 Scios Nova Inc Atrielle natriumuretische/gefässerweiterende polypeptide.
JPH0672157B2 (ja) * 1984-08-29 1994-09-14 味の素株式会社 新規ペプチド
US5057603A (en) * 1986-01-31 1991-10-15 Merck & Co., Inc. Peptides having ANF activity
US5449751A (en) * 1987-03-02 1995-09-12 Pharma Bissendorf Peptide Gmbh Cardiodilatin fragment, process for preparing same and use thereof
DE3878231T2 (de) * 1987-03-02 1993-05-27 Bissendorf Peptide Gmbh Neues cadiodilatin-fragment, prozess zu dessen herstellung und dessen anwendung.
US5204327A (en) * 1988-11-18 1993-04-20 Ashi Kasei Kogyo Kabushiki Kaisha Treatment of cerebral edema with anp pharmaceutical compositions
JPH10500969A (ja) * 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類

Also Published As

Publication number Publication date
AU2671795A (en) 1996-01-04
JP4130671B2 (ja) 2008-08-06
WO1995033769A1 (de) 1995-12-14
JP2005298526A (ja) 2005-10-27
US20030171536A1 (en) 2003-09-11
US20090240031A1 (en) 2009-09-24
US20100317600A1 (en) 2010-12-16
EP0763061A1 (de) 1997-03-19
US5767239A (en) 1998-06-16
US20060122371A1 (en) 2006-06-08
EP0763061B1 (de) 2002-10-30
JPH10500969A (ja) 1998-01-27
ATE226960T1 (de) 2002-11-15
IL113979A0 (en) 1995-10-31

Similar Documents

Publication Publication Date Title
ES2188665T3 (es) Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
ATE371670T1 (de) Reinigung von neurotrophinen
DK0877090T3 (da) Fremgangsmåde til produktion af L-aminosyrer
SE9603068D0 (sv) Process for purifying a protein
DE69807962D1 (de) Verfahren zur Reinigung von rohem 1,1,1,3,3-Pentafluorpropan
ATE201203T1 (de) Chirale methylphenyloxazolidinone
FI956295A7 (fi) Menetelmä rasvapitoisten luonnontuotteiden fraktiointiin tai puhdistukseen
ATE389023T1 (de) Kontrolle der schotendehiszenz
FI952148L (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
ES2070855T3 (es) Metodo para purificar una proteina.
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
ES2161790T3 (es) Procedimiento de separacion y de purificacion de proteinas dependientes de la vitamina k.
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
ITMI941969A0 (it) Processo per la purificazione di 2,6-diisopropilfenolo
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
DE69422467D1 (de) Fraktioniermethode für Nukleotidfragmente
ES2125938T3 (es) Procedimiento para la reactivacion de proteinas membranales purificadas.
DE69736180D1 (de) Behandlung von manischen erkrankungen
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
EP0735140A3 (en) Process for secretory protein production
TW368505B (en) A process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
PT1001929E (pt) Processo para o fabrico de acidos 3-ciano-2,4-di-halogeno-5-fluorobenzoicos
BG98888A (en) Method for the preparation of 3-acylestratrienes and acylbezenes
FR2758137B1 (fr) Procede de purification du pentafluoroethane par distillation extractive